Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease.
Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease.
复制标题
第二次粪便微生物群移植的时机以维持克罗恩病第一次治疗的长期益处
DOI：
10.1007/s00253-018-9447-x
复制
发表时间：
2019-01
影响因子：
5
通讯作者：
Zhang F
中科院分区：
文献类型：
--
作者：
Li P;Zhang T;Xiao Y;Tian L;Cui B;Ji G;Liu YY;Zhang F
越来越多的证据表明，粪便微生物群移植（FMT）可能是克罗恩病（CD）的一种有前途的治疗选择。然而，FMT治疗CD的频率仍不清楚。本研究旨在评价给予第二疗程FMT的最佳时机，以维持CD患者首次FMT的长期临床效果。本研究入组了69例接受过两次FMT并从第一次FMT中获益的活动性CD患者。在随访期间评估患者的临床反应、粪便微生物群和尿液代谢组。在总共69名患者中，对首次FMT维持临床应答的中位时间为125天（IQR，82.5-225.5）。69例患者中有56例对第二次FMT维持临床应答的时间为176.5天（IQR，98.5-280）。第一次FMT后每个患者的粪便微生物群组成更接近他/她的供体。与基线相比，第二个疗程FMT前患者的尿代谢特征存在显著差异，其特征为硫酸吲哚酚、4-羟基苯乙酸、肌酐、二甲胺、甘氨酰脯氨酸、马尿酸和氧化三甲胺（TMAO）增加。本研究表明，CD患者可以在首次FMT后4个月内接受第二个疗程的FMT，以维持首次FMT的临床获益。这得到了活动性CD患者中宿主微生物代谢变化的支持。试验注册：ClinicalTrials.gov，NCT 01793831。2013年2月18日注册。https://clinicaltrials.gov/ct2/show/NCT01793831? term= NCT 01793831&rank =1本文的在线版本（10.1007/s 00253 -018-9447-x）包含补充材料，授权用户可以使用。
Increasing evidence has shown that fecal microbiota transplantation (FMT) could be a promising treatment option for Crohn’s disease (CD). However, the frequency of FMT for CD treatment remains unclear. This study aimed to evaluate the optimal timing for administering the second course of FMT to maintain the long-term clinical effects from the first FMT for patients with CD. Sixty-nine patients with active CD who underwent FMT twice and benefited from the first FMT were enrolled in this study. Clinical response, stool microbiota, and urine metabolome of patients were assessed during the follow-up. The median time of maintaining clinical response to the first FMT in total 69 patients was 125 days (IQR, 82.5–225.5). The time of maintaining clinical response to the second FMT in 56 of 69 patients was 176.5 days (IQR, 98.5–280). The fecal microbiota composition of each patient post the first FMT was closer to that of his/her donor. Compared to that of the baseline, patients prior to the second course of FMT showed significant differences in urinary metabolic profiles characterized by increased indoxyl sulfate, 4-hydroxyphenylacetate, creatinine, dimethylamine, glycylproline, hippurate, and trimethylamine oxide (TMAO). This study demonstrated that patients with CD could be administered the second course of FMT less than 4 months after the first FMT for maintaining the clinical benefits from the first FMT. This was supported by the host–microbial metabolism changes in patients with active CD. Trial registration: ClinicalTrials.gov, NCT01793831. Registered 18 February 2013. https://clinicaltrials.gov/ct2/show/NCT01793831?term=NCT01793831&rank=1 The online version of this article (10.1007/s00253-018-9447-x) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
7.4
作者：
Cui B;Li P;Xu L;Zhao Y;Wang H;Peng Z;Xu H;Xiang J;He Z;Zhang T;Nie Y;Wu K;Fan D;Ji G;Zhang F
通讯作者：
Zhang F
影响因子：
4.9
作者：
Strauss, Jaclyn;Kaplan, Gilaad G.;Allen-Vercoe, Emma
通讯作者：
Allen-Vercoe, Emma
影响因子：
9.8
作者：
Kolho, Kaija-Leena;Korpela, Katri;de Vos, Willem M.
通讯作者：
de Vos, Willem M.
DOI：
10.1038/nrgastro.2017.88
发表时间：
2017-10
期刊：
Nature reviews. Gastroenterology & hepatology
影响因子：
--
作者：
Ni J;Wu GD;Albenberg L;Tomov VT
通讯作者：
Tomov VT
多次新鲜粪便微生物群移植可诱导并维持克罗恩病并发炎性肿块的临床缓解
影响因子：
4.6
作者：
He Z;Li P;Zhu J;Cui B;Xu L;Xiang J;Zhang T;Long C;Huang G;Ji G;Nie Y;Wu K;Fan D;Zhang F
通讯作者：
Zhang F